Skip to content

Addiction: all studies

Page 305 of 857: studies 3,041 to 3,050 of 8,563, newest first. Back to the addiction overview

Research

The effect of mindfulness training on the psychological state of high-level athletes: Meta analysis and system evaluation research.

Journal of Sports Sciences March 1, 2025 Jianjun Zhang, Jinxiu Sun, Yuchuan Zhou et al. 15 citations

To investigate the impact of mindfulness training on mindfulness, psychological resilience, flow state, subjective well-being, sports anxiety, sports depression, and psychological fatigue among elite athletes through a meta-analysis. Databases like PubMed, Web of Science, and others were searched for randomized controlled trials up to October 31, 2024. Included studies compared mindfulness...

DOI: 10.1080/02640414.2025.2468997 (opens in new tab) Full text (opens in new tab) Mindfulness training Elite athletes Mental state Meta-analysis

Is dosage of a meditation app associated with changes in psychological distress? It depends on how you ask.

Clinical Psychological Science March 1, 2025 Simon B. Goldberg, Ashley D Kendall, Matthew J. Hirshberg et al. 15 citations

Despite growing popularity, associations between dosage and outcomes in meditation app interventions have not been established. We examined this relationship using a range of operationalizations of dosage (e.g., minutes of use, days of use, number and type of activities completed) and strategies for modeling outcomes (e.g., ordinary least squares regression, multilevel modeling, latent class...

Beyond consciousness: Ethical, legal, and social issues in human brain organoid research and application.

European journal of cell biology March 1, 2025 Masanori Kataoka, Takuya Niikawa, Naoya Nagaishi et al. 22 citations

This study aims to provide a comprehensive review of the ethical, legal and social issues in human brain organoid research, with a view to different types of research and applications: in vitro research, transplantation into non-human animals, and biocomputing. Despite the academic and societal attention on the possibility that human brain organoids may be conscious, we have identified diverse...

Efficient and modular synthesis of ibogaine and related alkaloids.

Nature Chemistry March 1, 2025 Rishab N Iyer, David Favela, Andras Domokos et al. 22 citations

Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-traumatic stress disorder. Here we report a gram-scale,...

DOI: 10.1038/s41557-024-01714-7 (opens in new tab) Full text (opens in new tab) Ibogaine Natural compound Related alkaloids --10-fluoroibogamine +13

Allosteric inhibition of NMDA receptors by low dose ketamine.

Molecular Psychiatry March 1, 2025 Jamie A. Abbott, Han Wen, Beiying Liu et al. 14 citations

Ketamine, a general anesthetic, has rapid and sustained antidepressant effects when administered at lower doses. Anesthetic levels of ketamine reduce excitatory transmission by binding deep into the pore of NMDA receptors where it blocks current influx. In contrast, the molecular targets responsible for antidepressant levels of ketamine remain controversial. We used electrophysiology,...

Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses.

Neuropsychopharmacology March 1, 2025 Manoela V. Fogaça, Fernanda Daher, Marina R. Picciotto 22 citations

Major depressive disorder (MDD) is associated with disruptions in glutamatergic and GABAergic activity in the medial prefrontal cortex (mPFC), leading to altered synaptic formation and function. Low doses of ketamine rapidly rescue these deficits, inducing fast and sustained antidepressant effects. While it is suggested that ketamine produces a rapid glutamatergic enhancement in the mPFC, the...

Can We Better Understand, Diagnose, and Treat Ketamine-Induced Uropathy, and Can It Be Reversed? ICI-RS 2024.

Neurourology and urodynamics March 1, 2025 François Hervé, Patrik Aronsson, D Carolina Ochoa et al. 1 citation

Ketamine, a versatile anesthetic, has seen increased recreational use, leading to significant health issues, including ketamine-induced uropathy (KIU). KIU manifests with lower urinary tract symptoms (LUTS) and can involve the upper urinary tract. This study aims to provide a comprehensive overview of KIU, addressing its pathophysiology, diagnostic strategies, and treatment options; and to...

DOI: 10.1002/nau.25612 (opens in new tab) Full text (opens in new tab) Hydronephrosis Substance‐related disorders Uropathy Ketamine abuse +4

Clinical indicators of the suicide crisis and response to ketamine.

Journal of Affective Disorders March 1, 2025 Elizabeth D. Ballard, Lucinda Neely, Laura Waldman et al. 4 citations

This analysis sought to identify potential clinical targets for the suicide crisis. Characteristics of a useful clinical target include elevation at the time of suicide crisis and responsiveness to rapid-acting interventions. Suicidal ideation (SI), depression, and hopelessness were hypothesized to meet these criteria. Participants were 118 adults across the continuum of suicide risk, including...

The diverse effects of ketamine, jack-of-all-trades: a narrative review.

British Journal of Anaesthesia March 1, 2025 Nicholas D Richards, Simon J Howell, Mark C Bellamy et al. 20 citations

Ketamine, an N-methyl-D-aspartic acid receptor antagonist that was first discovered in 1962, has become established in anaesthesia providing dose-dependent anaesthetic, sedative, and analgesic effects. Ketamine, however, also acts on a wide range of other cellular targets, resulting in interesting and diverse effects on both physiological and pathological processes. Potential beneficial...

DOI: 10.1016/j.bja.2024.11.018 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonist Anaesthesia Anti-inflammatory properties Antidepressant effects +7

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

American Journal of Psychiatry March 1, 2025 Marjorie R. Levinstein, Reece C Budinich, Jordi Bonaventura et al. 49 citations

Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders...

DOI: 10.1176/appi.ajp.20240378 (opens in new tab) Full text (opens in new tab) Ketamine/esketamine #ketamine esketamine Ketalar Special k +4